Topics
July/August 2015 | Technology
A New Self-Testing System for Patients With AMD or DME
Changing treatment patterns often dictate the need for a change in disease detection.
Raj K. Maturi, MD
November 2, 2026
FDA Approves Lucamzi as Ranibizumab Biosimilar to Lucentis for Retinal Diseases
OpZira Completes Stage II Audit for AdaptDx Pro, Advances Plans for European CE Marking
October 30, 2026
Octant Receives FDA Orphan Drug Designation for OCT-980 for the Treatment of Retinitis Pigmentosa
VisioSurgical Solutions Begins Development of Compact Surgical Robot for Retinal Surgery
October 2026 Insert
Editorially Independent Content, Supported With Advertising From Asetllas
Editorially independent supported by Abbvie and Regenxbio
Free Print Subscription
Email Newsletter
Conference Calendar
